{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:34:49Z","timestamp":1790080489630,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21172011"],"award-info":[{"award-number":["21172011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673287"],"award-info":[{"award-number":["81673287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502905"],"award-info":[{"award-number":["81502905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ejmech.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T02:35:55Z","timestamp":1552012555000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors"],"prefix":"10.1016","volume":"170","author":[{"given":"Bin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zemei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-8939","authenticated-orcid":false,"given":"Runtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.03.003_bib1","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA cancer J. Clin."},{"key":"10.1016\/j.ejmech.2019.03.003_bib2","first-page":"489","article-title":"Local cancer recurrence: the realities, challenges, and opportunities for new therapies","volume":"68","author":"Mahvi","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2019.03.003_bib3","first-page":"177","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2019.03.003_bib4","first-page":"1","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Canc."},{"key":"10.1016\/j.ejmech.2019.03.003_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.03.003_bib6","first-page":"3159","article-title":"A\u00a0systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from january 2001 to october 2015","volume":"24","author":"O'Brien","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib7","first-page":"1","article-title":"Recent advances in cancer metabolism: a technological perspective","volume":"50","author":"Kang","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2019.03.003_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd3504","article-title":"Targeting cancer metabolism: a therapeutic window opens","volume":"10","author":"Vander Heiden","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.03.003_bib10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2019.03.003_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"Warburrg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.03.003_bib12","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.1016\/S0021-9258(18)47947-1","article-title":"The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters","volume":"262","author":"Noguchi","year":"1987","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.tibs.2012.04.003","article-title":"Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer","volume":"37","author":"Chaneton","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2019.03.003_bib14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.molcel.2012.01.001","article-title":"Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase","volume":"45","author":"Gao","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2019.03.003_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Luo","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.03.003_bib16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.biocel.2010.02.005","article-title":"Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells","volume":"43","author":"Mazurek","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib17","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1073\/pnas.1217157110","article-title":"M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation","volume":"110","author":"Morgan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2019.03.003_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.2000431","article-title":"Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth","volume":"2","author":"Hitosugi","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2019.03.003_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","article-title":"PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis","volume":"150","author":"Yang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.03.003_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.03.003_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nature11540","article-title":"Serine is a natural ligand and allosteric activator of pyruvate kinase M2","volume":"491","author":"Chaneton","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.03.003_bib22","first-page":"43","article-title":"Pyruvate kinase: function, regulation and role in cancer, Semin","volume":"43","author":"Israelsen","year":"2015","journal-title":"Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semcancer.2005.04.009","article-title":"Pyruvate kinase type M2 and its role in tumor growth and spreading","volume":"15","author":"Mazurek","year":"2005","journal-title":"Semin. Canc. Biol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4155\/fmc.14.70","article-title":"Activators of PKM2 in cancer metabolism","volume":"06","author":"Warner","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ardp.201500357","article-title":"Inhibitory and activating effects of some flavonoid derivatives on human pyruvate kinase isoenzyme M2","volume":"349","author":"Adem","year":"2016","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2019.03.003_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Anastasiou","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/jm901577g","article-title":"Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"53","author":"Boxer","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib28","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.bmcl.2013.03.090","article-title":"Discovery of 2-((1H-benzo[d]imidazole-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators","volume":"23","author":"Guo","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.03.003_bib29","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1016\/j.bmcl.2010.04.015","article-title":"Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"20","author":"Jiang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.03.003_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.14348\/molcells.2015.2314","article-title":"A\u00a0novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia","volume":"38","author":"Kim","year":"2015","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2019.03.003_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.chembiol.2012.07.021","article-title":"Small molecule activation of PKM2 in cancer cells induces serine auxotrophy","volume":"19","author":"Kung","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2017.11.023","article-title":"Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators","volume":"143","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib33","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.bmc.2017.05.004","article-title":"Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator","volume":"25","author":"Matsui","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/1535-7163.MCT-13-0026","article-title":"Pharmacologic activation of PKM2 slows lung tumor xenograft growth","volume":"12","author":"Parnell","year":"2013","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2019.03.003_bib35","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1016\/j.bmcl.2011.08.114","article-title":"2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"21","author":"Walsh","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.03.003_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bmcl.2013.12.028","article-title":"Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2)","volume":"24","author":"Xu","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.03.003_bib37","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1016\/j.bmcl.2012.08.054","article-title":"1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"22","author":"Yacovan","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.03.003_bib38","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1021\/acs.jmedchem.8b00241","article-title":"Natural product micheliolide (MCL) irreversibly activates pyruvate kinase M2 and suppresses leukemia","volume":"61","author":"Li","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib39","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1016\/j.bmc.2015.05.041","article-title":"New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds","volume":"23","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib40","first-page":"661","article-title":"Regioselective functionalization of 1H-pyrrolo[2,3-b]pyridine via its N-oxide","volume":"24","author":"Ohshiro","year":"1992","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2019.03.003_bib41","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1021\/jm101027s","article-title":"Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents","volume":"54","author":"Tung","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib42","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1021\/jm040063i","article-title":"N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy","volume":"47","author":"Tavares","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib43","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1021\/jo901835m","article-title":"Multi-gram scale synthesis of FR180204","volume":"74","author":"Patnaik","year":"2009","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12431","article-title":"PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis","volume":"7","author":"Liang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.03.003_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","article-title":"Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation","volume":"480","author":"Yang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.03.003_bib46","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ncb2629","article-title":"ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect","volume":"14","author":"Yang","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2019.03.003_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2013.06.008","article-title":"Regulation and function of pyruvate kinase M2 in cancer","volume":"339","author":"Yang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.03.003_bib48","first-page":"225","article-title":"A\u00a0critical review of the role of M2PYK in the Warburg effect","volume":"1871","author":"Harris","year":"2019","journal-title":"BBA-Rev. Cancer"},{"key":"10.1016\/j.ejmech.2019.03.003_bib49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41422-018-0086-7","article-title":"Pyruvate kinase M2 regulates homologous recombinationmediated DNA double-strand break repair","volume":"28","author":"Sizemore","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2019.03.003_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20111487","article-title":"Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression","volume":"209","author":"Goldberg","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2019.03.003_bib51","doi-asserted-by":"crossref","first-page":"15561","DOI":"10.1074\/jbc.M117.791343","article-title":"Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival","volume":"292","author":"Prakasam","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.03.003_bib52","first-page":"1","article-title":"PKM2 promotes cell migration and inhibits autophagy by mediating PI3K\/AKT activation and contributes to the malignant development of gastric cancer","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.03.003_bib53","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1021\/ol502447w","article-title":"Rhodium-catalyzed regioselective C-H chlorination of 7-azaindoles using 1,2-dichloroethane","volume":"16","author":"Qian","year":"2014","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.03.003_bib54","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/ol900150u","article-title":"Site-Selective azaindole arylation at the azine and azole rings via N-oxide activation","volume":"11","author":"Huestis","year":"2009","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.03.003_bib55","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bmcl.2014.12.093","article-title":"6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B","volume":"25","author":"Chen","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.03.003_bib56","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1039\/C6OB00179C","article-title":"Regioselective Ir(III)-catalyzed C\u2013H alkynylation directed by 7-azaindoles","volume":"14","author":"Liu","year":"2016","journal-title":"Org. Biomol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419302144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419302144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:56:55Z","timestamp":1777528615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419302144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":56,"alternative-id":["S0223523419302144"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.003","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}